Abiopharma

Geron is a commercial-stage biopharmaceutical company focused on research, development, and commercialization of the Companys internally developed first-in-class telomerase inhibitor for the treatment of hematologic malignancies. RYTELO(R) (imetelstat) is approved in the United States and Europe for treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with a telomerase inhibitor approved by the FDA and the EC, Geron is exploring the broad potential of imetelstat across multiple myeloid hematologic malignancies. In addition to its Phase 3 trial for JAK inhibitor relapsed/refractory myelofibrosis (R/R MF), Geron has programs assessing imetelstat in additional indications, as a single agent and in combination with current standard of care therapies through early-stage clinical trials.The company earns revenue through RYTELO sales and possesses global rights to imetelstat.

Additional info from NASDAQ:
Geron is a commercial-stage biopharmaceutical company focused on research, development, and commercialization of the Companys internally developed first-in-class telomerase inhibitor for the treatment of hematologic malignancies. RYTELO(R) (imetelstat) is approved in the United States and Europe for treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with a telomerase inhibitor approved by the FDA and the EC, Geron is exploring the broad potential of imetelstat across multiple myeloid hematologic malignancies. In addition to its Phase 3 trial for JAK inhibitor relapsed/refractory myelofibrosis (R/R MF), Geron has programs assessing imetelstat in additional indications, as a single agent and in combination with current standard of care therapies through early-stage clinical trials.The company earns revenue through RYTELO sales and possesses global rights to imetelstat.